Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: A prospective impact study

BJU International

Volumn 110, Issue 2, 2012, Pages 180-187

  Van Vugt, Heidi A ^a   Roobol, Monique J ^a   Van Der Poel, Henk G ^b   Van Muilekom, Erik H A M ^b   Busstra, Martijn ^a   Kil, Paul ^c   Oomens, Eric H ^d   Leliveld, Annemarie ^e   Bangma, Chris H ^a   Korfage, Ida ^a   Steyerberg, Ewout W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c CPRLab   (Netherlands)

^d AMPHIA HOSPITAL   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Active surveillance; Compliance; Prediction model; Prostate cancer; Risk calculator; Treatment choice

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER RISK; CANCER SCREENING; CANCER STAGING; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

AGED; CHOICE BEHAVIOR; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK ASSESSMENT; UROLOGY; WATCHFUL WAITING;

EID: 84863494178     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10679.x     Document Type: Article

References (30)

1. Draisma G, Etzioni R, Tsodikov A et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101: 374-83
2. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981-90 (Pubitemid 34814727)
3. Gosselaar C, Roobol MJ, Schroder FH. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int 2005; 95: 231-7 (Pubitemid 40283154)
4. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-31
5. van den Bergh RC, Roemeling S, Roobol MJ et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009; 55: 1-8
6. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010; 102: 950-8
7. Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 1792-7 (Pubitemid 37254930)
8. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007; 177: 107-12; discussion 112
9. Dong F, Kattan MW, Steyerberg EW et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 2008; 180: 150-4
10. Bul MDN, Steyerberg EW, de la Roza G et al. Updating the prostate cancer risk indicator for contemporary biopsy schemes. C an J Urol 2011; 1 8: 5625-9
11. Razavi D, Gandek B. Testing Dutch and French translations of the SF-36 Health Survey among Belgian angina patients. J Clin Epidemiol 1998; 51: 975-81 (Pubitemid 28527153)
12. van der Bij AK, de Weerd S, Cikot RJ, Steegers EA, Braspenning JC. Validation of the dutch short form of the state scale of the Spielberger State-Trait Anxiety Inventory: considerations for usage in screening outcomes. C ommunity Genet 2003; 6: 84-7 (Pubitemid 37323446)
13. van den Bergh RC, Korfage IJ, Borsboom GJ, Steyerberg EW, Essink-Bot ML. Prostate cancer-specific anxiety in Dutch patients on active surveillance: validation of the memorial anxiety scale for prostate cancer. Qual Life Res 2009; 18: 1061-6
14. Koedoot N, Molenaar S, Oosterveld P et al. The decisional conflict scale: further validation in two samples of Dutch oncology patients. Patient Educ Couns 2001; 45: 187-93 (Pubitemid 33109005)
15. Beekman AT, van Limbeek J, Deeg DJ, Wouters L, van Tilburg W. A screening tool for depression in the elderly in the general population: the usefulness of Center for Epidemiological Studies Depression Scale (CES-D). Tijdschr Gerontol Geriatr 1994; 25: 95-103 (Pubitemid 24232918)
16. Sanderman R, Arindell WA, Ranchor AV, Eysenck HJ, Eysenck SBG. Het Meten Van Persoonlijkheidskenmerken Met De Eysenck Personality Questionnaire (EPQ): Een Handleiding. Noordelijk Centrum Voor Gezondheidsvraagstukken. Groningen, The Netherlands: Rijksuniversiteit Groningen, 1995
17. van Vugt HA, Roobol MJ, Venderbos LD et al. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator. Eur J Cancer 2010; 46: 669-77
18. van den Bergh RC, van Vugt HA, Korfage IJ et al. Disease insight and treatment perception of men on active surveillance for early prostate cancer. BJU Int 2009; 105: 322-8
19. Roth A, Nelson CJ, Rosenfeld B et al. Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC). Psychosomatics 2006; 47: 340-7
20. Roberts RE, Vernon SW. The Center for Epidemiologic Studies Depression Scale: its use in a community sample. Am J Psychiatry 1983; 140: 41-6 (Pubitemid 13221717)
21. Eysenck HJ, Eysenck SBG. Manual of the Eysenck Personality Scales (EPS Adults). London, UK: Hodder & Stoughton, 1991
22. Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P. Making decisions about treatment for localized prostate cancer. BJU Int 2002; 89: 255-60 (Pubitemid 34158457)
23. Gwede CK, Pow-Sang J, Seigne J et al. Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer 2005; 104: 1381-90 (Pubitemid 41356153)
24. Gorin MA, Soloway CT, Eldefrawy A, Soloway MS. Factors That Influence Patient Enrollment in Active Surveillance for Low-risk Prostate Cancer. Urology 2011; 77: 588-91
25. Zeliadt SB, Ramsey SD, Penson DF et al. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer 2006; 106: 1865-74 (Pubitemid 43673200)
26. van den Bergh RC, Essink-Bot ML, Roobol MJ et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009; 115: 3868-78
27. Reilly BM, Evans AT. Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann Intern Med 2006; 144: 201-9 (Pubitemid 46780691)
28. Hunink MGM, Glasziou PP, Siegel JE et al. Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge, UK: Cambridge University Press, 2001
29. Boevee SJ, Venderbos LD, Tammela TL et al. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer. Eur J Cancer 2010; 46: 3082-9
30. Brehaut JC, Stiell IG, Graham ID. Will a new clinical decision rule be widely used? The case of the Canadian C-spine rule. A cad Emerg Med 2006; 1 3: 413-20